SCHEDULE: Austria Capital LLC Discloses 4.99% Passive Stake in Klotho Neurosciences Inc.
Beneficial Ownership Report
Austria Capital LLC has reported a beneficial ownership of 4.99% of Klotho Neurosciences Inc.'s common stock, totaling 1,621,470 shares, indicating a passive investment strategy.
Summary
- Austria Capital LLC filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Klotho Neurosciences Inc.
- Austria Capital LLC beneficially owns 1,621,470 shares of Klotho Neurosciences Inc. common stock.
- This ownership represents 4.99% of the class, calculated based on 32,494,389 shares outstanding as of May 14, 2025.
- The shares outstanding figure was obtained from a Form 10-Q filed by Klotho Neurosciences Inc. on May 15, 2025, for the quarter ended March 31, 2025.
- Austria Capital LLC holds sole voting power and sole dispositive power over all 1,621,470 shares.
- The aggregate amount of shares beneficially controlled by Austria Capital LLC is subject to a contractually stipulated 4.99% ownership restriction.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership, with no inherent positive or negative operational or financial news for Klotho Neurosciences Inc.
Positives
- The disclosure of a significant 4.99% stake by Austria Capital LLC indicates institutional interest in Klotho Neurosciences Inc.
Negatives
- The contractually stipulated 4.99% ownership restriction limits Austria Capital LLC's ability to increase its stake beyond this threshold, signifying a passive investment approach rather than an activist one.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Klotho Neurosciences Inc., which may limit the potential for strategic shifts driven by this investor.
Future Outlook
This Schedule 13G filing is a factual disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Klotho Neurosciences Inc.'s future performance or strategic outlook.
Management Comments
- Austria Capital LLC certifies that, to the best of its knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Klotho Neurosciences Inc., and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a standard regulatory disclosure for passive institutional investors acquiring a significant stake (below 5%) in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics within the neuroscience sector.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of the event which required the filing of this statement (beneficial ownership threshold met/changed). |
| 05/15/2025 | Date Klotho Neurosciences Inc. filed its Form 10-Q, providing the shares outstanding count. |
| 06/05/2025 | Date the Schedule 13G was signed by Austria Capital LLC. |
Keywords
Klotho Neurosciences, Austria Capital, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.